Sign up for the QMED & MD+DI Daily newsletter.
April 20, 2020
1 Min Read
Image by Gerd Altmann on Pixabay
Pi-Cardia Ltd. has raised $27 million to develop a catheter-based solution to treat heart valve calcification. The Rehovot, Israel-based company said the financing was led by Sonfinnova Partners and joined by Professor Jacques Séguin, Chairman of the company, with further participation from existing investors.
The financing follows the successful completion of the company’s First-In-Human studies of the Leaflex Catheter.
Pi-Cardia said its technology performs mechanical scoring of valve calcification, restoring leafelts’ mobility and improving valve hemodynamics. The company added that the device can be used for patients who are not planning to undergo a transcatheter aortic valve replacement (TAVR) and it can be a means to defer those patients who may be too young for the procedure.
It can also be a preparatory step for improving the outcome of TAVR in heavily calcified and bicuspid aortic valves.
In a release, Pi-Cardia’s CEO and Founder, Erez Golan said, “With our very promising early results, we are now ready to move to the next stage and establish the long-term safety and efficacy of Leaflex as a standalone treatment for patients with aortic stenosis. We have an ambitious plan ahead of us, and we are dedicated to making Pi-Cardia's technology the next revolution in the treatment of structural heart disease.”
You May Also Like
Masimo Takes Apple's Hail Mary Pass in StrideFeb 29, 2024|3 Min Read
Top 40 Medical Device CompaniesFeb 29, 2024|2 Min Read
2024 Planning Guide for Medical Manufacturing AutomationFeb 29, 2024|1 Min Read
Adverse Events Reported for Hologic BioZorb Marker, BioZorb LP MarkerFeb 28, 2024|2 Min Read